Malaria Detection and Speciation, Qualitative by Real-Time PCR
Ordering Recommendation

Not a first-line test for malaria screening. Refer to Parasites Smear (Giemsa Stain), Blood (0049025) or Malaria, Rapid Screen and Giemsa Stain (2001547) for screening and diagnosing acute disease.

Qualitative Real-Time Polymerase Chain Reaction
1-3 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Lavender (EDTA) or pink (K2EDTA). 
Specimen Preparation
Transport 1 mL whole blood. (Min: 0.5 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Heparinized specimens. 
Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 week 
Reference Interval
Interpretive Data
This qualitative test is intended only for the speciation of suspected malaria infections. It is not intended to monitor treatment or to be used on repeat specimens for evaluation of parasitic clearance. A positive result may still be obtained in the absence of visible parasites.

Detection of asymptomatic parasitemia in individuals from malaria-endemic areas is possible. Therefore, this test should only be used in conjunction with patient travel history and symptoms consistent with malaria. Only circulating parasites within the blood will be detected in this assay. Latent phase hypnozoites of Plasmodium ovale and Plasmodium vivax may not be detected.

Mixed infections (eg, multiple Plasmodium spp. present) may not be accurately identified if parasitemia is significantly higher for one of the Plasmodium spp.

This test will not detect other blood-borne parasites such as Babesia spp. and Trypanosomes, which may have similar clinical presentation. A negative result on this assay does not rule out the presence of PCR inhibitors in the patient specimen or assay-specific nucleic acid in concentrations below the level of detection by the assay.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
Component Test Code*Component Chart NameLOINC
2004964Malaria Speciation PCR, P. falciparum41447-4
2004966Malaria Speciation PCR, P. knowlesi47085-6
2004968Malaria Speciation PCR, P. vivax41450-8
2004970Malaria Speciation PCR, P. malariae41448-2
2004972Malaria Speciation PCR, P. ovale41449-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Plasmodium falciparum
  • Plasmodium knowlesi
  • Plasmodium malariae
  • Plasmodium ovale
  • Plasmodium vivax